Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04441996 · ClinicalTrials.gov registry record · Phase 4
Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT04441996 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 20 participants.
The verdict
NCT04441996, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
Many patients with Coronavirus Disease 2019 (COVID-19) have atypical blood clots. These blood clots can occur in either veins or arteries and be large, like in stroke or heart attack, or very tiny, called microthrombi. Some patients with COVID-19 even have blood clots despite being on anti-clotting medications. Blood with increased viscosity does not flow through the body normally, in the same way that syrup, a highly viscous liquid, and water, a minimally viscous liquid, flow differently. The researchers believe that hyperviscosity may contribute to blood clots and organ damage seen in patients with severe COVID-19. Plasma exchange removes a patient's plasma, which contains the large sticky factors that the researchers believe are increasing viscosity, and replaces it with plasma from healthy donors. In addition to providing important information about plasma exchange as a treatment in COVID-19 for patients, this study will provide data to justify resource and staffing decisions. This study will enroll 20 participants who are critically ill from COVID-19. Participants will be randomized to receive therapeutic plasma exchange (TPE) or standard of care (SOC).
Interventions
- OTHER Standard of care
- BIOLOGICAL Therapeutic plasma exchange (TPE)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-07-17 |
| Est. Completion | 2021-03-18 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04441996
The ClinicalTrials.gov registry entry for NCT04441996 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of care is the first listed.
NCT04441996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04441996 about?
NCT04441996 is a clinical study titled "Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity". Many patients with Coronavirus Disease 2019 (COVID-19) have atypical blood clots. These blood clots can occur in either veins or arteries and be large, like in stroke or heart attack, or very tiny, called microthrombi. Some patients with COVID-19 even have blood clots despite being on anti-clotting ...
What is the current status of trial NCT04441996?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2020-07-17. Estimated completion is 2021-03-18.
What interventions are being tested in trial NCT04441996?
The interventions under investigation include: Standard of care (OTHER), Therapeutic plasma exchange (TPE) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04441996?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.